Özet

Background: In this study, we investigated the clinical importance and possibility of mean platelet volume to be a predictive marker for acute mechanical valve thrombosis.

Methods: Mean platelet volume was measured in 28 consecutive patients (mean age 47.3±12.8 years) with mechanical valve thrombosis and 91 control subjects (mean age 46.1±5.8 years). In the study group, blood samples were collected at the first admission (group 1, first measurement) and in the postoperative routine control after discharge (group 1, second measurement). The first control group (group 2) was defined by having a mechanical valve with no history of thrombosis of the mechanical valve. The second control group (group 3) was selected in a consecutive manner from the catheterized cardiac patients who proved to have normal coronary angiograms. Diagnosis of mechanical valve obstruction was based on clinical examination, echocardiography, and cinefluoroscopy.

Results: Mean platelet volume was significantly higher in group 1 (first measurement) patients than in group 1 (second measurement), group 2 and group 3 patients (p<0.05). There were slightly higher mean platelet volume values in group 1 (second measurement) than in group 2 and group 3, although they were not statistical significance (p>0.05).

Conclusion: It was shown for the first time that patients with mechanical valve thrombosis have higher mean platelet volumes than control subjects. Therefore, mean platelet volume might be used as a follow-up marker of thrombosis in patients with mechanical valve thrombosis.

Platelet activation plays a crucial role in the prothrombotic events leading to mechanical valve obstruction (MVO). Increased platelet reactivity, as well as shortened bleeding time, is associated with increased platelet volume.[1,2] Higher mean platelet volume (MPV) values have been observed in more patients with stroke and acute myocardial infarction, unstable angina pectoris (USAP), coronary artery ectasia, preeclampsia, and renal artery stenosis than in control subjects.[3-7] However, so far no studies have assessed the relationship between MPV and mechanical valve thrombosis.

Thus, this study examines for the first time the spontaneous MPV variability during the acute phase of a thrombosed mechanical valve in 28 consecutive patients.

Yöntem

This study was performed during the recovery process of the patients and included the file recording system and operation notes. Permission for the study was obtained from the local ethics committee. Exclusion criteria were prior myocardial infarction, coronary artery disease, cerebrovascular events, hematological disorders, and acute or chronic infection. Between 2006 and 2009, 47 patients with MVO were surgically treated at Türkiye Yüksek İhtisas Hospital. Follow-up data was available for 39 patients (82%) with a mean follow-up of 6.4±1.3 months. In seven patients, there was only pannus in the mechanical valves. Four of them were excluded by MVO with a history of cerebrovascular or cardiovascular events. In 28 patients (the study group), there was MVO due to thrombosis. Ninety-one age and gender-matched patients were determined for two control groups.

The diagnosis of mechanical valve obstruction was based on clinical examinations and diagnostic procedures. The main clinical signs of obstruction were dyspnea, congestive heart failure, and embolism. Diagnosis was established in all patients by echocardiography and cinefluoroscopy.

In the study group, blood samples were collected upon admission before the operation (group 1 first measurement) and in postoperative routine control after discharge (mean 6.4 month) (group 1 second measurement). The first control group (group 2) was defined by having a mechanical valve with no history of thrombosed mechanical valve (TMV). The second control group (group 3) consisted of 59 subjects who were selected in a consecutive manner from the catheterized patients during the same study period and who proved to have normal coronary angiograms. In group 1 (second measurement) and group 2, the patient’s international normalized ratio (INR) was between 2.5-3.5 when the blood samples were collected.

Blood samples were taken in the supine position from the antecubital vein with a 20-gauge needle by applying minimal tourniquet force. The blood sample, which was used for the full blood count and MPV values, was drawn into a Vacutainer tube (BD Vacutainer Systems, Belliver Industrial Estate, Plymouth, UK) containing 0.04 ml of the 7.5% K3 salt of ethylenediaminetetraacetic acid (EDTA). These blood samples were analyzed after two hours of venipuncture by a Beckman Coulter LH 750 Analyzer (Miami, Florida, USA).

Statistical analysis
Continuous variables were given as the median ± standard deviation; categorical variables were defined as percentages. A chi-square test was used to compare differences of frequencies in patient characteristics. The other statistical differences of continuous variables between groups were determined using the one-way ANOVA and Tukey tests. Statistical significance was defined as p<0.05.

Bulgular

One hundred and nineteen consecutive patients were included in this controlled clinical study. The average age of the patients was 46.4±12 years and 82.36% were women. Baseline demographic and operative data, INR, platelet counts, white blood cell count (WBC-C), and red blood cell count (RBC-C) are summarized in tables 1 and 2.

Table 1: Demographic and operative characteristics of the study population

Table 2: Laboratory data and characteristics of the study population

Female gender had a significant frequency in all of these groups (p<0.01). Mitral valve replacement was found to be significantly elevated in groups 1 and 2 (p<0.05). In addition, 71.42% of patients had additional pannus in group 1 (1^st measurement).

There were no significant differences in red blood cell and platelet count between the groups (p>0.05). White blood cell count was higher in group 1 (1^st measurement) than in the others (p<0.05).

In group 1 (1^st measurement), 82.15% of patients were receiving subtherapeutic doses of anticoagulants (INR <2) at the time of diagnosis.

Mean platelet volume was found to be significantly elevated in patients in group 1 (1^st measurement) (11.8±1.1 fl) compared with group 1 (2^nd measurement) (p<0.05), group 2 (p<0.05), and group 3 (p<0.05). There were higher MPV values in group 1 (2nd measurement) than in group 2 and group 3, although they were not statistically significant (p>0.05).

Tartışma

In our study group, we determined admission MPV, a marker of platelet reactivity, and WBC, a marker of inflammation, to be independent predictors of thrombosed mechanical valve patients. To our knowledge, this study has examined for the first time the relationship between MPV and thrombosed mechanical valves. We found that patients with thrombosed mechanical valves had significantly higher MPV values than control subjects.

Mean platelet volume is an indicator of platelet activation, which has an important role in the pathophysiology of thrombosis. Large platelets that contain more dense granules are metabolically and enzymatically more active than small platelets and have higher thrombotic potential. They express higher levels of prothrombotic substances, thromboxane A2, serotonin, b-thromboglobulin, and procoagulatory surface proteins, such as P-selectin and glycoprotein IIIa.[7-12] Previously, it was suggested that an elevated WBC-C might be a marker of a hypercoagulable state.[13] The induction of monocyte procoagulant activity with either interleukin 6 (IL-6) or interleukin 8 (IL-8), which were shown to be overexpressed in leucocytes in acute myocardial infarction (MI) patients, has been proposed as a possible link between inflammation and thrombosis in developing intravascular thrombus.[13] Furthermore, it was shown that on the surface of monocytes, IL-6 and IL-8 caused an increase in tissue factor expression, which with factor Vlla initiates the extrinsic pathway of the coagulation cascade.[14-16] In our study, MPV and WBC-C were found to be significantly elevated in patients in Group 1 (1^st measurement) compared with the other groups. There was thrombosis in only Group 1 (1^st measurement) patients.

In previous studies, increased MPV was found to b e a ssociated w ith u nstable a ngina p ectoris, acute MI, coronary artery ectasia, and congestive heart failure.[1,5,7,9,12,17] In addition, several reports have demonstrated that there is a close relationship between MPV and cerebrovascular disease.[4,5] However, no previous study has examined the relationship between MPV and mechanical valves; hence, we determined to investigate MPV values in patients with thrombosed mechanical valves. We demonstrated that MPV values were more elevated in Group 1(1^st measurement) than in the other groups.

It is a known fact that increased platelet activation and aggregation are closely related to mechanic valve thrombosis. In previous reports, different methods were used to analyze the platelet activation: optical aggregometry, a platelet function analyzer (PFA-100), a platelet reactivity test or platelet aggregate ratio, flow cytometry, and thromboxane B(2) generation. All tests have limitations in their use due to complex preanalytical factors, reduced specificity, and poor reproducibility. However, MPV is a simple marker not requiring an advanced or expensive technology.[18]

Our study shows that MPV has clinical importance. Higher MPV seems to be an independent risk factor for TMV. Pizzulli et al.[9] suggest that because platelets stay in the circulation for 7-11 days, they might be detected days before symptoms appear. Similarly, Martin et al.[8] have indicated a correlation between higher MPV and recurrence or death after the first MI in their prospective study.[8] In our study group, MPV values were more elevated on admission before the operation than six months after discharge. We believe the same correlation might exist between MPV and TMV. In routine control, days before MVO symptoms, elevated MPV might be a suspect for TMV. However, to show a possible predictive value for TMV, more prospective studies with higher patient groups should be performed. We can only suggest that MPV and WBC-C might be a valuable and advantageous sign.

In closing, our study is the first to display a significant increase in MPV and WBC-C in patients with MVT. We believe that MPV and WBC-C might be valuable in the prediction of TMV and in planning the need for additional therapy to improve outcomes in patients who have mechanical valves.

Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding
The authors received no financial support for the research and/or authorship of this article.

Kaynaklar

1) Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002;117:399-404.

2) Dalby Kristensen S, Milner PC, Martin JF. Bleeding time and platelet volume in acute myocardial infarction-a 2 year follow-up study. Thromb Haemost 1988;59:353-6.

3) Jakubowski JA, Adler B, Thompson CB, Valeri CR, Deykin D. Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction. J Lab Clin Med 1985;105:271-6.

4) O’Malley T, Langhorne P, Elton RA, Stewart C. Platelet size in stroke patients. Stroke 1995;26:995-9.

5) Butterworth RJ, Bath PM. The relationship between mean platelet volume, stroke subtype and clinical outcome. Platelets 1998;9:359-64.

6) Cameron HA, Phillips R, Ibbotson RM, Carson PH. Platelet size in myocardial infarction. Br Med J (Clin Res Ed) 1983;287:449-51.

7) Sen N, Tavil Y, Yazici HU, Hizal F, Açikgöz SK, Abaci A, et al. Mean platelet volume in patients with coronary artery ectasia. Med Sci Monit 2007;13:CR356-9.

8) Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338:1409-11.

9) Pizzulli L, Yang A, Martin JF, Lüderitz B. Changes in platelet size and count in unstable angina compared to stable angina or non-cardiac chest pain. Eur Heart J 1998;19:80-4.

10) Henning BF, Zidek W, Linder B, Tepel M. Mean platelet volume and coronary heart disease in hemodialysis patients. Kidney Blood Press Res 2002;25:103-8.

11) Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol 1992;14:281-7.

12) Trowbridge EA, Martin JF. The platelet volume distribution: a signature of the prethrombotic state in coronary heart disease? Thromb Haemost 1987;58:714-7.

13) Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000;102:2329-34.

14) Marx N, Neumann FJ, Ott I, Gawaz M, Koch W, Pinkau T, Schömig A. Induction of cytokine expression in leukocytes in acute myocardial infarction. J Am Coll Cardiol 1997;30:165-70.

15) Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, Gawaz M, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997;17:3399-405.

16) Katircioğlu SF, Ulus AT, Yamak B, Ozsöyler I, Birincioğlu L, Taşdemir O. Acute mechanical valve thrombosis of the St. Jude medical prosthesis. J Card Surg 1999;14:164-8.

17) Erne P, Wardle J, Sanders K, Lewis SM, Maseri A. Mean platelet volume and size distribution and their sensitivity to agonists in patients with coronary artery disease and congestive heart failure. Thromb Haemost 1988;59:259-63.

18) Haubelt H, Simon M, Anders Ch, Hellstern P. Platelet function tests for monitoring of acetylsalicylic acid: clinical significance in antiplatelet treatment. Hamostaseologie 2004;24:196-202.